Display options
Cite
Kader A, Miyatani K, Takaya S, et al. Changes in Standard Treatments and Postoperative Outcomes for Advanced Gastric Cancer at One Institute over an 11-Year Period. Yonago Acta Med. 2015;58(2):77-80
Kader, A., Miyatani, K., Takaya, S., Matsunaga, T., Fukumoto, Y., Osaki, T., Saito, H., Otani, S., Wakatsuki, T., & Ikeguchi, M. (2015). Changes in Standard Treatments and Postoperative Outcomes for Advanced Gastric Cancer at One Institute over an 11-Year Period. Yonago acta medica, 58(2), 77-80.
Kader, Abdul, et al. "Changes in Standard Treatments and Postoperative Outcomes for Advanced Gastric Cancer at One Institute over an 11-Year Period." Yonago acta medica vol. 58,2 (2015): 77-80.
Kader A, Miyatani K, Takaya S, Matsunaga T, Fukumoto Y, Osaki T, Saito H, Otani S, Wakatsuki T, Ikeguchi M. Changes in Standard Treatments and Postoperative Outcomes for Advanced Gastric Cancer at One Institute over an 11-Year Period. Yonago Acta Med. 2015 Jun;58(2):77-80. Epub 2015 Aug 18. PMID: 26306057; PMCID: PMC4546959.
Copy Download .nbib Format: NLM
Share it on

Yonago Acta Med. 2015 Jun;58(2):77-80. Epub 2015 Aug 18.

Changes in Standard Treatments and Postoperative Outcomes for Advanced Gastric Cancer at One Institute over an 11-Year Period.

Yonago acta medica

Abdul Kader, Kozo Miyatani, Seigo Takaya, Tomoyuki Matsunaga, Yoji Fukumoto, Tomohiro Osaki, Hiroaki Saito, Shinji Otani, Toshiro Wakatsuki, Masahide Ikeguchi

Affiliations

  1. Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504, Japan.

PMID: 26306057 PMCID: PMC4546959

Abstract

BACKGROUND: Reportedly, the recently established postoperative adjuvant chemotherapies (ADJs) with tegafur and uracil (UFT) or fluoropyrimidine S (S-1) show better survival than surgery alone in patients with advanced gastric cancer (GC). We analyzed chronological changes in postoperative prognosis of patients with advanced GC in our institute, and investigated the efficacy of ADJ in patients with stage II-III GC.

METHODS: Of 143 patients with stage II-III GC who underwent curative gastrectomy at Tottori University Hospital between 1998 and 2008, three died with operative complications within 1 month after surgery. The remaining 140 patients were followed to the end of 2013. We compared disease-free survival (DFS) and clinicopathological differences between 82 patients who underwent gastrectomy during 1998-2002 (Group A) and 58 patients who underwent gastrectomy during 2003-2008 (Group B).

RESULTS: Operative quality, as represented by number of dissected lymph nodes, was similar in both groups, but the recurrence rate of Group A (51.2%) was higher than in Group B (37.9%, P = 0.12) and the 5-year DFS rate of Group B (62.3%) was higher than that of Group A (50.2%, P = 0.095). In stage II, the 5-year DFS rate of patients in Group B (73.3%) was similar to Group A (77%), but at tumor stage III, the 5-year DFS rate of patients in Group B increased to 48.7%, compared with 33.1% of Group A. Between 2003 and 2008, S-1 was widely used as ADJ for stage II-III GC.

CONCLUSION: Postoperative ADJ with S-1 improved DFS of patients with stage III gastric cancer.

Keywords: S-1; adjuvant chemotherapy; gastric cancer; tegafur and uracil

References

  1. Br J Surg. 2007 Dec;94(12):1468-76 - PubMed
  2. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  3. Gastric Cancer. 2011 Jun;14(2):101-12 - PubMed
  4. J Clin Oncol. 2006 May 10;24(14):2137-50 - PubMed
  5. Anticancer Drugs. 1996 Jul;7(5):548-57 - PubMed
  6. N Engl J Med. 2007 Nov 1;357(18):1810-20 - PubMed
  7. J Clin Oncol. 2011 Nov 20;29(33):4387-93 - PubMed

Publication Types